Last reviewed 2026-08-25
BPC-157's gut healing data in rodents is among the most consistent in its literature — it was originally derived from a protein found in gastric juice. As everywhere else, that has not been tested in controlled human trials. The gap matters especially here, because inflammatory bowel disease has effective approved treatments, and substituting an untested compound for them carries real consequences.
BPC-157 is a synthetic fragment related to a protein found in human gastric juice, so the gut is arguably its most biologically plausible application, and the rodent work on intestinal healing is extensive.
But this is also the goal where self-treating carries the most risk. Crohn's disease and ulcerative colitis are serious conditions with genuinely effective approved therapies, and delayed treatment causes lasting damage.
'Leaky gut' is a separate matter — intestinal permeability is a real, measurable phenomenon, but it is not an established standalone diagnosis, and treatments sold for it are typically supported by neither.
Every entry carries the level of human evidence for this use — not the compound’s approval status for something else.
| Peptide | Evidence for this goal | FDA status | Typical cost/mo |
|---|---|---|---|
| BPC-157 | Animal studies only | Research | $100–$300 |
| KPV | Animal studies only | Research | $80–$250 |
| LL-37 | Animal studies only | Research | $150–$400 |
Derived from a gastric protein; the most consistent part of its animal literature is intestinal healing.
The catch: Rodent evidence only. Should not displace evidence-based treatment for diagnosed inflammatory bowel disease.
Anti-inflammatory tripeptide studied specifically in models of intestinal inflammation.
The catch: Animal and cell work only.
Antimicrobial peptide with a role in gut mucosal defence.
The catch: Its role in immunity is established; using it as a gut therapy is not.
Nothing here has controlled human trial evidence for gut conditions. For inflammatory bowel disease, approved therapies do have that evidence.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.
BPC-157 requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
Rodent studies show effects on intestinal healing and barrier integrity. No controlled human trial has tested this. 'Leaky gut' itself is not an established standalone diagnosis, though intestinal permeability is a real measurable phenomenon.
No. Inflammatory bowel disease has approved treatments with real trial evidence, and delaying them causes cumulative bowel damage. None of the compounds here has been tested in controlled human trials for these conditions.
Our directory lists clinics whose own websites show they offer peptide therapy. We verify what each one actually provides rather than taking a listing at face value.
Browse the provider directory